<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33413517</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-00420-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">TDP-43 proteinopathy is a pathological hallmark of many neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). So far, there is no therapy available for these neurodegenerative diseases. In addition, the impact of TDP-43 proteinopathy on neuronal translational profile also remains unknown.</AbstractText><AbstractText Label="METHODS">Biochemical, immunohistology and assay-based studies were done with cell cultures and transgenic mice models. We also used Ribotag with microarray and proteomic analysis to determine the neuronal translational profile in the mice model of ALS/FTD.</AbstractText><AbstractText Label="RESULTS">Here, we report that oral administration of a novel analog (IMS-088) of withaferin-A, an antagonist of nuclear factor kappa-B (NF-&#x138;B) essential modulator (NEMO), induced autophagy and reduced TDP-43 proteinopathy in the brain and spinal cord of transgenic mice expressing human TDP-43 mutants, models of ALS/FTD. Treatment with IMS-088 ameliorated cognitive impairment, reduced gliosis in the brain of ALS/FTD mouse models. With the Ribotrap method, we investigated the impact of TDP-43 proteinopathy and IMS-088 treatment on the translation profile of neurons of one-year old hTDP-43<sup>A315T</sup> mice. TDP-43 proteinopathy caused translational dysregulation of specific mRNAs including translational suppression of neurofilament mRNAs resulting in 3 to 4-fold decrease in levels type IV neurofilament proteins. Oral administration of IMS-088 rescued the translational defects associated with TDP-43 proteinopathy and restored the synthesis of neurofilament proteins, which are essential for axon integrity and synaptic function.</AbstractText><AbstractText Label="CONCLUSIONS">Our study revealed that induction of autophagy reduces TDP-43 pathology and ameliorates the translational defect seen in mice models of ALS/FTD. Based on these results, we suggest IMS-088 and perhaps other inducers of autophagy should be considered as potential therapeutics for neurodegenerative disorders with TDP-43 proteinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sunny</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phaneuf</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutej</LastName><ForeName>Hejer</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriz</LastName><ForeName>Jasna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-9072-5667</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, 2601, Chemin de la Canardi&#xe8;re, Quebec City, QC, G1J 2G3, Canada. jean-pierre.julien@fmed.ulaval.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>JPJ holds shares in IMSTAR Therapeutics which provided the IMS-088 compound. All other authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33413517</ArticleId><ArticleId IdType="pmc">PMC7792109</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00420-5</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-00420-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E. Advances in genetics, vol. 91: Elsevier; 2015. p. 1&#x2013;53. 10.1016/bs.adgen.2015.07.001.</Citation></Reference><Reference><Citation>Liu EY, et al. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421. e1406. doi: 10.1016/j.celrep.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Invest. 2019;129:1581&#x2013;1595. doi: 10.1172/JCI123931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI123931</ArticleId><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T. Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology. 2014;34:578&#x2013;588. doi: 10.1111/neup.12138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12138</ArticleId><ArticleId IdType="pubmed">25196969</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919&#x2013;931. doi: 10.1016/S0140-6736(16)00737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138:54&#x2013;70. doi: 10.1111/jnc.13588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13588</ArticleId><ArticleId IdType="pubmed">27306735</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9:1104&#x2013;1120. doi: 10.1021/pr901076y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr901076y</ArticleId><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, et al. Futsch/MAP 1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis. J Neurosci. 2014;34:15962&#x2013;15974. doi: 10.1523/JNEUROSCI.2526-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2526-14.2014</ArticleId><ArticleId IdType="pmc">PMC4244467</ArticleId><ArticleId IdType="pubmed">25429138</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder P, Chu J-F, Chatterjee B, Swamy KB, Shen C-KJ. Co-regulation of mRNA translation by TDP-43 and fragile X syndrome protein FMRP. Acta Neuropathol. 2016;132:721&#x2013;738. doi: 10.1007/s00401-016-1603-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1603-8</ArticleId><ArticleId IdType="pmc">PMC5073124</ArticleId><ArticleId IdType="pubmed">27518042</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A, et al. Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Hum Mol Genet. 2017;26:1407&#x2013;1418. doi: 10.1093/hmg/ddx035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx035</ArticleId><ArticleId IdType="pmc">PMC6075552</ArticleId><ArticleId IdType="pubmed">28158562</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien J-P, Dupr&#xe9; N. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 2016;4:70. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Rahimian R, Phaneuf D, Julien J-P. Withania somnifera reverses transactive response DNA binding protein 43 proteinopathy in a mouse model of amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neurotherapeutics. 2017;14:447&#x2013;462. doi: 10.1007/s13311-016-0499-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0499-2</ArticleId><ArticleId IdType="pmc">PMC5398980</ArticleId><ArticleId IdType="pubmed">27928708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang I-F, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci. 2012;109:15024&#x2013;15029. doi: 10.1073/pnas.1206362109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B&#x2013;mediated pathogenic pathways. J Exp Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Banu MR, Ibrahim M, Prabhu K, Rajasankar S. Withaferin-A protects the nigral dopamine neuron and recovers motor activity in aged rats. Cells Tissues Organs. 2020;208:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31982873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Jackson SS, Coughlin EE, Coon JJ, Miyamoto S. Covalent modification of the NF-&#x3ba;B essential modulator (NEMO) by a chemical compound can regulate its ubiquitin binding properties in vitro. J Biol Chem. 2014;289:33161&#x2013;33174. doi: 10.1074/jbc.M114.582478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.582478</ArticleId><ArticleId IdType="pmc">PMC4246077</ArticleId><ArticleId IdType="pubmed">25296760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Santo-Yamada Y, Wada K. Stress-induced impairment of inhibitory avoidance learning in female neuromedin B receptor-deficient mice. Physiol Behav. 2003;78:303&#x2013;309. doi: 10.1016/S0031-9384(02)00979-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-9384(02)00979-4</ArticleId><ArticleId IdType="pubmed">12576129</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187&#x2013;3201. doi: 10.1093/brain/aww237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pmc">PMC5840881</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId></ArticleIdList></Reference><Reference><Citation>Charron G, Guy L-G, Bazinet M, Julien J-P. Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain. J Biol Chem. 1995;270:30604&#x2013;30610. doi: 10.1074/jbc.270.51.30604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.51.30604</ArticleId><ArticleId IdType="pubmed">8530496</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle JP, et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell. 2008;135:749&#x2013;762. doi: 10.1016/j.cell.2008.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.10.029</ArticleId><ArticleId IdType="pmc">PMC2763427</ArticleId><ArticleId IdType="pubmed">19013282</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutej H, et al. Diverging mRNA and protein networks in activated microglia reveal SRSF3 suppresses translation of highly upregulated innate immune transcripts. Cell Rep. 2017;21:3220&#x2013;3233. doi: 10.1016/j.celrep.2017.11.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.11.058</ArticleId><ArticleId IdType="pubmed">29241548</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis. 2012;45:862&#x2013;870. doi: 10.1016/j.nbd.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.002</ArticleId><ArticleId IdType="pubmed">22198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Trocoli A, Djavaheri-Mergny M. The complex interplay between autophagy and NF-&#x3ba;B signaling pathways in cancer cells. Am J Cancer Res. 2011;1:629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189824</ArticleId><ArticleId IdType="pubmed">21994903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3:36. doi: 10.1186/s40478-015-0212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0212-4</ArticleId><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xf4;t&#xe9; F, Collard J-F, Julien J-P. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell. 1993;73:35&#x2013;46. doi: 10.1016/0092-8674(93)90158-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90158-M</ArticleId><ArticleId IdType="pubmed">8462101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron. 1994;13:975&#x2013;988. doi: 10.1016/0896-6273(94)90263-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(94)90263-1</ArticleId><ArticleId IdType="pubmed">7946341</ArticleId></ArticleIdList></Reference><Reference><Citation>Collard J-F, C&#xf4;t&#xe9; F, Julien J-P. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature. 1995;375:61&#x2013;64. doi: 10.1038/375061a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375061a0</ArticleId><ArticleId IdType="pubmed">7536898</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J-P. Neurofilaments and motor neuron disease. Trends Cell Biol. 1997;7:243&#x2013;249. doi: 10.1016/S0962-8924(97)01049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(97)01049-0</ArticleId><ArticleId IdType="pubmed">17708953</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu JM, Nguyen MD, Julien JP. Late onset of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol. 1999;147:531&#x2013;544. doi: 10.1083/jcb.147.3.531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.147.3.531</ArticleId><ArticleId IdType="pmc">PMC2151189</ArticleId><ArticleId IdType="pubmed">15132161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, et al. Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol Psychiatry. 2015;20:986&#x2013;994. doi: 10.1038/mp.2015.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.45</ArticleId><ArticleId IdType="pmc">PMC4514553</ArticleId><ArticleId IdType="pubmed">25869803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, et al. Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. Transl Psychiatry. 2018;8:1&#x2013;12. doi: 10.1038/s41398-018-0194-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0194-7</ArticleId><ArticleId IdType="pmc">PMC6109052</ArticleId><ArticleId IdType="pubmed">30143609</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35:320&#x2013;327. doi: 10.1016/j.mcn.2007.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.03.007</ArticleId><ArticleId IdType="pubmed">17481916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh K, et al. Withaferin a induced impaired autophagy and unfolded protein response in human breast cancer cell-lines MCF-7 and MDA-MB-231. Toxicol in Vitro. 2017;44:330&#x2013;338. doi: 10.1016/j.tiv.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2017.07.025</ArticleId><ArticleId IdType="pubmed">28782635</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Julien J-P, Kriz J. Early-stage treatment with Withaferin a reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:217&#x2013;233. doi: 10.1007/s13311-014-0311-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0311-0</ArticleId><ArticleId IdType="pmc">PMC4322065</ArticleId><ArticleId IdType="pubmed">25404049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q-Z, et al. Protection against cerebral infarction by Withaferin a involves inhibition of neuronal apoptosis, activation of PI3K/Akt signaling pathway, and reduced intimal hyperplasia via inhibition of VSMC migration and matrix metalloproteinases. Adv Med Sci. 2017;62:186&#x2013;192. doi: 10.1016/j.advms.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2016.09.003</ArticleId><ArticleId IdType="pubmed">28282606</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishnavi K, et al. Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences. PloS one. 2012;7:e44419. doi: 10.1371/journal.pone.0044419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044419</ArticleId><ArticleId IdType="pmc">PMC3433425</ArticleId><ArticleId IdType="pubmed">22973447</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 3beta-methoxy derivation of Withaferin-a attenuates its anticancer potency: bioinformatics and molecular evidences. Med Aromat Plants. 2015;4:2167&#x2013;0412.100021.</Citation></Reference><Reference><Citation>Chaudhary A, et al. 2, 3-Dihydro-3&#x3b2;-methoxy Withaferin-a protects normal cells against stress: molecular evidence of its potent cytoprotective activity. J Nat Prod. 2017;80:2756&#x2013;2760. doi: 10.1021/acs.jnatprod.7b00573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jnatprod.7b00573</ArticleId><ArticleId IdType="pubmed">29043807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585. doi: 10.1038/ng1362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1362</ArticleId><ArticleId IdType="pubmed">15146184</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of &#x3b1;-synucleinopathy. PLoS One. 2010;5:e9313. doi: 10.1371/journal.pone.0009313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009313</ArticleId><ArticleId IdType="pmc">PMC2824828</ArticleId><ArticleId IdType="pubmed">20174468</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilman P, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-&#x3b2; levels in a mouse model of Alzheimer&#x2019;s disease. PLoS One. 2010;5:e9979. doi: 10.1371/journal.pone.0009979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009979</ArticleId><ArticleId IdType="pmc">PMC2848616</ArticleId><ArticleId IdType="pubmed">20376313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G. Autophagy: a druggable process that is deregulated in aging and human disease. J Clin Invest. 2015;125:1&#x2013;4. doi: 10.1172/JCI78652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78652</ArticleId><ArticleId IdType="pmc">PMC4382251</ArticleId><ArticleId IdType="pubmed">25654544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang L, Joo D, Sun S-C. NF-&#x3ba;B signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. doi: 10.1038/sigtrans.2017.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sigtrans.2017.23</ArticleId><ArticleId IdType="pmc">PMC5661633</ArticleId><ArticleId IdType="pubmed">29158945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>